Crossmark

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study

Crossref DOI link: https://doi.org/10.1038/s41698-025-01018-0

Published Online: 2025-07-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hou, Zhenlin

Liao, Leen

Xiao, Weiwei

Sui, Qiaoqi

Han, Kai

Xiao, Binyi

Li, Yuan

Mei, Weijian

Yu, Jiehai

Hong, Zhigang

Chen, Qichen

Song, Ruyue

Li, Dandan

Zhang, Xiaoshi

Wang, Qiaoxuan

Pan, Zhizhong

Jiang, Wu

Ding, Peirong
Funding

Funding for this research was provided by:

Fostering Program for NSFC Young Applicants (Tulip Talent Training Program) of Sun Yat-sen University Cancer Center (TTP-SYSUCC-gzrpy-2021-12, TTP-SYSUCC-2024yfd12)

National Natural Science Foundation of China (82473395)

Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0032)

Guangzhou Science and Technology Key Research and Development Program (2024B03J0092)
License Information

Text and Data Mining valid from 2025-07-12

Version of Record valid from 2025-07-12
More Information

Article History

Received: 28 March 2025

Accepted: 17 June 2025

First Online: 12 July 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below